Skip to Content

Generex Biotechnology to Exhibit At American Association ofDiabetes Educators Annual Meeting & Exhibition

WORCESTER, Mass., Aug. 2, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that that it will be exhibiting at the American Association of Diabetes Educators Annual Meeting & Exhibition, August 1 - 4, 2007 in St. Louis, Missouri.

At the convention, Generex will demonstrate its proprietary technologies for the development of products that will help patients with diabetes control and manage the disease. Such products include Generex Oral-lyn(tm), the Company's proprietary oral insulin spray product, and Glucose RapidSpray(tm), the Company's proprietary confectionary product for people who want or need additional glucose in their diets. Dr. Gerald Bernstein, the Company's Vice-President for Medical Affairs and a former President of the American Diabetes Association, will be present at the Generex booth to discuss the Company's products.

The American Association of Diabetes Educators is a multidisciplinary professional membership organization of healthcare professionals dedicated to integrating successful self-management as a key outcome in the care of people with diabetes and related conditions. Diabetes education, also known as diabetes self-management training (DSMT), is a collaborative process through which people with or at risk for diabetes gain the knowledge and skills needed to modify behavior and successfully self-manage the disease and its related conditions. The intervention aims to achieve optimal health status, better quality of life and reduce the need for costly healthcare. Diabetes education is most often provided by diabetes educators (nurses, dietitians, pharmacists, doctors, exercise physiologists, podiatrists and social workers, among others). Diabetes educators give people with diabetes the knowledge, skills and tools they need to successfully manage their diabetes and avoid many of the complications associated with the disease.

About Generex

Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and before the end of 2007 the Company expects to begin Phase 3 trials of the product in the United States, Canada and Europe.

Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

Posted: August 2007